| Bioactivity | Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases[1][2]. |
| Target | PDE9 |
| In Vivo | Irsenontrine (0.3, 3.3 mg/kg; p.o.) maleate exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats[1].Irsenontrine (1 mg/kg; p.o.) maleate and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone[1]. |
| Name | Irsenontrine maleate |
| CAS | 1630083-70-3 |
| Formula | C26H26N4O7 |
| Molar Mass | 506.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1 [2]. Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. [3]. Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases |
Irsenontrine maleate
CAS: 1630083-70-3 F: C26H26N4O7 W: 506.51
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleat
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.